The U.S. and E.U. pharmaceutical markets are major targets for international drug companies looking to grow their global sales. Geopolitical uncertainty and the push to improve supply-chain resiliency are driving onshoring efforts and making the importation of drug products, particularly from Asia, increasingly challenging. Partnering with a contract development and manufacturing organization (CDMO) that provides end-to-end services with compliant production, packaging, and distribution capabilities in the U.S. and a point of entry into the European market can avoid import issues while reducing program timelines and risk.